Ambulatory Care Survey, National Hospital Discharge Survey etc.) in terms of data elements' design, efficiency of a hierarchical structure and data integrity, data security, etc. Comparative analysis has been conducted using a tool that aggregates questions on qualitative registries' metrics. RESULTS: Compared to other registries, NVDRS has a well-defined goal, sufficient for the development of a PH registry (to assist the design of PH interventions for a reduction of mortality due to violent deaths). NVDRS is a population based, confidential, incident-driven, computerized information system. NVDRS represents a new generation of systems with the highest level of data complexity because of the aggregation of multiple data sources obtained from different state agencies. NVDRS encompasses essential registry functions and attributes sufficient to accomplish the system's major goals. It has well defined core elements, which allows for many types of analysis. CONCLUSIONS: A comparative analysis of NVDRS demonstrates that goals, design and structure of this system promote best practices for the PH patient registries. We developed an Excel-based Markov model of the natural history of HPV and cervical cancer using a cycle length of six months for transitioning between health states (Normal, HPV, Cervical Intraepithelial Neoplasia (CIN) 1, CIN 2, CIN 3, Cervical Cancer (Stages 1 to 4), and death. Health states are stratified by HPV type (16, 18, 31, 45, 52, Other Oncogenic,. Using a lifetime simulation of 12-year old girls, the model was calibrated to current data for two European countries (The Netherlands, UK (UK)). Calibration endpoints included: 1)Age-specific HPV prevalence; 2)HPV type distribution in cervical disease; 3)Prevalence of pre-cancerous lesions; and 4)Age-specific cervical cancer incidence and mortality. Observed screening practices and coverage (three-yearly for UK, five-yearly for The Netherlands) were used for calibrating to a screened environment. Transition probabilities were varied, within established ranges, to reproduce calibration endpoints. RESULTS: Model-predicted outcomes correlated well with observed data for both UK and The Netherlands. Overall, HPV prevalence was comparable for UK (model-predicted = 7.1%; observed = 9.6%) and The Netherlands (model-predicted = 6.4%; observed = 9.2%). Differences between countries were observed in other endpoints, such as crude cervical cancer incidence per 100,000 (UK: model-predicted = 10.4, observed = 10.2; The Netherlands: model-predicted = 8.5, observed = 8.1), as well as cervical cancer mortality per 100,000 (UK: modelpredicted = 5.2, observed = 5.1; The Netherlands: modelpredicted = 2.8, observed = 2.9). CONCLUSIONS: A model of the natural history of HPV and cervical cancer was successfully calibrated to two countries. It is important to calibrate to several epidemiological endpoints in countries so that health economic benefits of vaccine can be accurately projected in future cost-effectiveness analyses. to identify all relevant cost-effectiveness evaluations investigating one or more of these four treatments in autoimmune disorders. RESULTS: Fifteen full economic evaluations were identified. There were 12 for rheumatoid arthritis, 2 for Crohn's disease, and 1 for ankylosing spondylitis. There were 5 studies in the UK, 4 in the United States, 2 studies in Sweden, one joint study in Sweden and in the UK, one study in France, one study in The Netherlands and one study in Spain. The majority of evaluations used modeling to project the long-term cost-effectiveness of treatments. In general, cost-effectiveness ratios were favorable for the treatment of patients with refractory disease not responding to previous treatments whether in rheumatoid arthritis or ankylosing spondylitis. In Crohn's disease, biologic treatments were not cost-effective in the treatment of perianal fistulae, or for maintenance therapy in patients with moderate to severe active disease. Due to the high cost of these treatments, costeffectiveness ratios were less favorable for maintenance therapy across diseases. CONCLUSION: Modeling the cost-effectiveness of more expensive biologic treatments in autoimmune disorders presents significant challenges due to the chronic and recurring nature of diseases such as rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. A better understanding of these issues will be useful to researchers developing future models for these disease areas but also for other autoimmune disorders for which biologic agents may be appropriate such as, for example, ulcerative colitis, psoriasis and psoriatic arthritis.
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PMC11 DEVELOPMENT OF A GLOBAL HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER: CALIBRATION TO THE UNITED KINGDOM AND NETHERLANDS

Ferko
PMC12 THE COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS: A STRUCTURED REVIEW OF THE LITERATURE
PMC13 APPLYING EXPECTANCY-VALUE MODEL TO UNDERSTAND HEALTH PREFERENCE-AN EXPLORATORY STUDY
Zhang XH 1 , Xie F 1 , Wee HL 1 , Thumboo J 2 , Li SC 1 1 National University of Singapore, Singapore, 2 Singapore General Hospital, Singapore, Singapore OBJECTIVES: To investigate factors influencing health preference with expectancy-value model (EVM). METHODS: EVM, a model widely used to explore underlying factors of attitudes was applied to study health preference, which was categorized as attitude in psychology. The factors include attitudinal attributes (AAs) and external variables. AAs are measured in a sum of multiplications of one's subjective probability (expectancy) and perceived value of attributes. In one-to-one interviews, four AAs identified in focus group discussion, namely, reduction in quality of life (RQoL), burden to family (BTF), dependence on others (DOO) and inability to work (ITW) were assessed using 7-point Likert scales to measure expectancy and value of each attribute. Health preference was measured using visual analogue scales (VAS, range 0-100). Univariate analyses were used to identify external variables (age, gender, ethnicity, education, housing, marital status, and concurrent chronic diseases) that cause significant difference in VAS. Multiple linear regression model (MLR) was used to investigate the explanative power of AAs and possible significant external variable(s) separately or in combination. RESULTS: Twenty-five Chinese and 21 Indians (mean (SD) age: 45.0 (15.55) years, 55.6% female) were interviewed. Ethnicity was identified as the only independent variable causing significant difference in VAS (p < 0.05). RQoL, BTF, DOO, ITW were found to explain the variation of VAS of 26.5%, 27.2%, 23.2%, 17.1% respectively in separate MLR models (p < 0.05). Combining ethnicity together with the sum of AAs explained up to 27.3% of the variation in VAS, while a model with ethnicity alone only accounted for 10.7% (p < 0.05). When MLR was done to examine different predicting power of AAs by ethnicity, ITW failed to predict VAS of Indians (0.3%, p = 0.80) while the other 3 AAs moderately explained from 9.1% to 22.9% of the variation p < 0.05). CONCLUSIONS: EVM may be helpful in explaining the variations in health preference and predicting important factors. We assessed reporting of cost-effectiveness thresholds in the literature to examine prevailing judgements about society's willingness-to-pay per QALY. We hypothesized that stated thresholds were directly related to an author's home country GDP per capita and that they have increased over time to reflect economic growth. METHODS: We evaluated 573 costeffectiveness analyses (CEAs) published between 1998-2003 and listed in the Tufts-NEMC CEA registry. We scrutinized authors' judgments regarding appropriate cost/QALY thresholds (e.g., that an incremental cost/QALY ratio under $50,000/QALY represents "good value for money"), and examined whether thresholds differed by author's home country GDP per capita (2000 values) . RESULTS: CEAs most frequently originated from the US (n = 320), UK (n = 68), Canada (n = 45), and The Netherlands (n = 35). Of 573 studies, 325 CEAs (57%) stated an explicit threshold. The most frequent thresholds used in the US were $50,000/QALY (52%), followed by the classification proposed by Laupacis (CAN$20,000-CAN$100,000) (16%), and $100,000/QALY (11%). Most Canadian studies (65%) used the Laupacis classification, and most UK studies (52%) used GBP30,000/QALY. The prevailing US threshold ($50,000/ QALY) corresponded to approximately 1.4 times US GDP per capita, whereas the UK threshold (GBP30,000/QALY) was approximately 1.9 times UK GDP per capita. The lower and upper limits of the Laupacis classification used in Canada corresponded to 0.6 to 2.9 times Canadian GDP per capita. Thresholds used by authors have not changed significantly over time and where not inflated to address inflation or economic growth. CONCLUSIONS: Thresholds used in the US, UK, and Canada do not appear to be related to GDP per capita, and have not increased over time. More research is needed to determine appropriate country-specific or disease-specific thresholds. Mechanisms for updating thresholds to reflect inflation rates or changes in GDP are warranted.
PMC14 PREVAILING JUDGMENTS ABOUT SOCIETY'S WILLINGNESS TO PAY FOR A QALY: DO THEY VARY BY COUNTRY? HAVE THEY CHANGED OVER TIME?
Greenberg
PMC15 INTERNET-BASED UTILITY ELICITATION OF A GENERIC HEALTH STATE
Livengood K University of Southern California, Yorba Linda, CA, USA OBJECTIVES: The primary objective of this study was to determine the feasibility of an internet-based method for eliciting population based preferences for generic health states using the standard gamble procedure. METHODS: An internet-based standard gamble utilizing a chance board and a "ping-pong" search procedure was introduced to twenty-five respondents who were primarily recruited via e-mail solicitation. The respondents were asked to elicit their preference for an EQ-5D generic health state (21221). The same set of respondents were asked to elicit their preference for their current health state using a internetbased visual analog scale. RESULTS: Fifty-eight percent of the 25 respondents were male. Eighty percent of the respondents were either health care professionals or academic-based health service researchers, and the remainder were from the general population. The majority of the respondents were White. Four respondents were Hispanic and one was Asian. The mean age of the respondents was 39.7 years. Both the standard gamble and visual analog scale elicitation results were normally distributed (Kolmogorov-Smirnov, p > 0.05). The mean elicited preference for the generic health state using standard gamble was 0.8726 (s.d. 0.095), and the mean visual analog scale elicited preference for the respondents' current health state was 0.8721 (s.d. 0.088). CONCLUSION: An internet-based approach for eliciting preference for a generic health state using a sophiticated standard gamble procedure appears to be an efficient means for performing such inquiry.
PMC16 GENERAL HEALTH STATUS AND PATIENT SATISFACTION: ARE THEY MUTUALLY EXCLUSIVE OR CORRELATED OUTCOMES?
Sansgiry S, Sail K, Abbass I, Murty S University of Houston, Houston, TX, USA OBJECTIVE: The objective of this study was to analyze the relationship between general health status and patient satisfaction by conducting a meta-analysis on two previously conducted studies. METHODS: Data collected from two cross-sectional studies performed in 1997 and 2001 were pooled. Data collected in 1997 was obtained from 737 patients taking a Selective Serotonin Reuptake Inhibitor selected randomly from a prescription claims database of a managed care company in Utah. Data collected in 2001 was obtained randomly from 443 patients filling prescriptions at 10 pharmacies located in the Houston, Texas. General health status was measured using the SF-12 scale. Patient satisfaction with the services provided by the health plan was measured using an eight item scale. The satisfaction scale across the two data sets was standardized to a 0-100 scale, where a score of 100 was considered highly satisfied. Data were coded and analyzed to report descriptive and correlation analyses. RESULTS: The pooled dataset resulted in 1180 observations. The mean age of the respondents was 47.02 ± 11.41 years (range 10 to 82) of which majority were females (72.6%). Data showed that the respondents had low physical composite scores (PCS) (48.34 ± 10.08) and mental composite scores (MCS) (46.39 ± 11.04) on the SF-12 scale. The mean patient satisfaction score was 71.18 (± 17.89). Correlation analysis indicated there was no association of either the PCS or the MCS with overall patient satisfaction scores (p > 0.05). However, there was a positive association of individual items like health coverage provided by the plan and out of pocket expenses paid by patient for health
